抗胸腺细胞球蛋白治疗再生障碍性贫血研究进展被引量：2

Progress of antithymocyte globulin in aplastic anemia treatment

导出

摘要再生障碍性贫血(再障)是一种严重的血液病。对于不具备全相合同胞供体(MSD)进行造血干细胞移植(HSCT)治疗条件的患者,免疫抑制治疗(IST)为其首选药物疗法。抗胸腺细胞球蛋白(ATG)是有效治疗获得性再障的免疫抑制剂,本文综述ATG治疗再障的近期研究进展。 Aplastic anemia is a severe hematopoietic disease. The patients of hematopoietic stem cell transplantation （HSCT）, who do not have the matched sibling donor （MSD）, should use immunosuppressive therapy （IST）. Antithymocyte globulin （ATG） is the most effective immunosuppressive agent for the treatment of acquired aplastie anemia. This review describes the recent research progress on ATG in the treatment of aplastic anemia.

作者谢晓恬

机构地区同济大学附属同济医院儿科/小儿血液专科

出处《世界临床药物》 CAS 2015年第5期289-293,共5页 World Clinical Drug

基金上海市科委重点项目(11JC1411900) 上海市卫生局适宜技术推广项目(2013SY073)

关键词再生障碍性贫血抗胸腺细胞球蛋白(ATG) 免疫抑制治疗(IST) aplastic anemia antithymocyte globulin （ATG） immunosuppressive therapy （IST）

分类号 R973 [医药卫生—药品] R552 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献3

1吴迪炯,叶宝东,胡致平,沈一平,沈建平,林圣云,陈明涛,刘永林,周郁鸿.Bone Marrow Angiogenesis in Patients Presenting with Differential Chinese Medicine Syndrome:Correlation with the Clinico-pathological Features of Aplastic Anemia[J].Chinese Journal of Integrative Medicine,2013,19(12):905-912. 被引量：20
2谢晓恬.《2009年版英国再生障碍性贫血诊断与治疗指南》要点归纳[J].中华实用儿科临床杂志,2014,29(3):161-164. 被引量：23
3谢晓恬,赵惠君,覃大卫.抗胸腺细胞球蛋白治疗儿童再生障碍性贫血药代动力学研究[J].中华实用儿科临床杂志,2013,28(15):1134-1137. 被引量：6

二级参考文献17

1孙伟正,杨东光,刚宏林.慢性再生障碍性贫血中医辨证分型与MHC-DRB1*等位基因的相关性研究[J].中医杂志,2004,45(6):450-452. 被引量：3
2张蕾,陈世伦,陈文明,刘晋伟.多发性骨髓瘤血管内皮生长因子和白细胞介素-6相互作用的研究[J].中华内科杂志,2005,44(2):85-88. 被引量：11
3Jeong DC,Chung NG,Kang H J. Epidemiology and clinical longterm outcome of childhood aplastic anemia in Korea for 15 years:retrospective study of the Korean Society of Pediatric Hematology Oncology (KSPHO)[J].Journal of Pediatric Hematology Oncology,2011,(03):172-178.
4Atta EH,Dias DS,Marra VL. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia:a single-center retrospective study[J].Annals of Hematology,2010,(09):851-859.
5Chang MH,Kim KH,Kim HS. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia[J].European Journal of Haematology,2010,(02):154-159.
6Marsh JC,Ball SE,Cavenagh J. Guidelines for the diagnosis and management of aplastic anaemia[J].British Journal of Haematology,2009,(01):43-70.
7Young NS,Bacigalupo A,Marsh JC. Aplastic anemia:pathophysiology and treatmen[J].Biology of Blood and Marrow Transplantation,2010,(01):S119-S125.
8Song EY,Kang HJ,Shin HY. Association of human leukocyte antigen class Ⅱ alleles with response to immunosuppressive therapy in Korean aplastic anemia patients[J].Human Immunology,2010,(01):88-92.
9Malcovati L,de Latour RP,Risitano A. Aplastic anemia & MDS International Foundation (AA&MDSIF):Bone Marrow Failure Disease Scientific Symposium 2010[J].Leukemia Research,2011,(03):291-294.
10Ehrlich P. Ueber einem fall yon anamie mit bemerkungen ober regenerative veranderungen des knochenmarks[J].Charite-Annalen,1888.300-309.